Protagonist Therapeutics, Inc.
PTGX · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $5 | $6 | $28 | $171 |
| % Growth | -15% | -80.4% | -83.4% | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $5 | $6 | $28 | $171 |
| % Margin | 100% | 100% | 100% | 100% |
| R&D Expenses | $40 | $37 | $36 | $35 |
| G&A Expenses | $11 | $11 | $12 | $9 |
| SG&A Expenses | $11 | $11 | $12 | $9 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $51 | $48 | $48 | $44 |
| Operating Income | -$46 | -$42 | -$19 | $127 |
| % Margin | -985.2% | -758% | -68.2% | 74.3% |
| Other Income/Exp. Net | $7 | $7 | $8 | $7 |
| Pre-Tax Income | -$39 | -$35 | -$12 | $134 |
| Tax Expense | $0 | $0 | $0 | $2 |
| Net Income | -$39 | -$35 | -$12 | $132 |
| % Margin | -834.9% | -627% | -41.2% | 77.2% |
| EPS | -0.62 | -0.55 | -0.19 | 2.11 |
| % Growth | -12.7% | -189.5% | -109% | – |
| EPS Diluted | -0.62 | -0.55 | -0.19 | 1.98 |
| Weighted Avg Shares Out | 64 | 64 | 63 | 62 |
| Weighted Avg Shares Out Dil | 64 | 64 | 63 | 66 |
| Supplemental Information | – | – | – | – |
| Interest Income | $7 | $7 | $8 | $7 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $1 |
| EBITDA | -$39 | -$42 | -$19 | $127 |
| % Margin | -827.2% | -752.6% | -67.3% | 74.6% |